Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 10 (11), 1026-34

Oral Treatment for Multiple Sclerosis

Affiliations
Review

Oral Treatment for Multiple Sclerosis

Joep Killestein et al. Lancet Neurol.

Abstract

Background: The armamentarium for the treatment of relapsing-remitting multiple sclerosis (RRMS) is increasing rapidly. Several oral treatments have shown benefit and will generate much interest because of the convenience of such administration. However, availability of convenient oral drugs will not necessarily translate into clinical effectiveness and safety. Here, we provide an interim report about the mechanisms of action, and efficacy and safety results that have been reported since January, 2010, for five new oral drugs. Additionally, we draw attention to issues that neurologists and patients will encounter when considering the use of new oral drugs.

Recent developments: Positive results have been reported for five new oral drugs for RRMS--fingolimod, cladribine, teriflunomide, laquinimod, and dimethyl fumarate--in phase 3 studies; a few new oral drugs are likely to be approved for RRMS soon. WHERE NEXT?: Emerging oral treatments are ushering in a new era in the treatment of MS, providing not only new treatment options but also new challenges. Since data for some of the new drugs have not been reported in peer-reviewed journals yet and safety profiles are not yet fully developed, opinions about the use of these new oral drugs in practice are preliminary and tentative. Practice will evolve with time as information and experience accumulates. Of importance will be results from comparator trials, information about management of patients with breakthrough disease, results from long-term safety studies, and results of studies to assess the potential for neuroprotective effects of the new drugs.

Similar articles

  • Oral Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis
    RH Thomas et al. Am J Health Syst Pharm 72 (1), 25-38. PMID 25511835. - Review
    With the approval of three oral drugs for RRMS-fingolimod, teriflunomide, and dimethyl fumarate-the therapeutic strategy for RRMS has evolved to include options that are …
  • Emerging Oral Drugs for Multiple Sclerosis
    C Gasperini et al. Expert Opin Emerg Drugs 13 (3), 465-77. PMID 18764723. - Review
    It is unknown whether these oral drugs could be used as first-line treatment for MS; this will depend mostly on their safety profile. Alternatively, these drugs could be …
  • [Oral Treatments in Multiple Sclerosis]
    JE Meca-Lallana et al. Med Clin (Barc) 143 Suppl 3, 23-9. PMID 25732946. - Review
    The development of new disease-modifying drugs (DMD) in relapsing-remitting multiple sclerosis (RRMS), which share the common denominator of oral administration, consider …
  • New Oral Drugs for Multiple Sclerosis
    C Gasperini et al. Neurol Sci 30 Suppl 2, S179-83. PMID 19882371. - Review
    Disease-modifying treatments are now available in relapsing-remitting and secondary progressive multiple sclerosis (MS), and their beneficial effects have been shown in s …
  • Oral Therapies for Multiple Sclerosis: A Review of Agents in Phase III Development or Recently Approved
    R Gold. CNS Drugs 25 (1), 37-52. PMID 21128693. - Review
    Several disease-modifying therapies are approved for the management of multiple sclerosis (MS). While reasonably effective, these therapies require long-term parenteral s …
See all similar articles

Cited by 32 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback